诱导疗法 确定移植受体中珀福林和Granzyme B转录物的分布
Dino Pipic1,2, Marianne Rasmussen2, Qais W Saleh1,2
1Institute of Molecular Medicine, Clinical Institute, University of Southern Denmark, 5000 Odense, Denmark.
Biomedicines
|June 27, 2024
概括
免疫抑制疗法影响移植患者的免疫细胞标记物Perforin和Granzyme B. 胸球蛋白诱导疗法显著降低了这些转录,影响了移植后的免疫防御.
科学领域:
- 免疫学 免疫学 免疫学
- 移植科学 移植科学
- 分子生物学分子生物学
背景情况:
- 周围血液单核细胞利用Perforin和Granzyme B进行病原体防御.
- 了解免疫抑制疗法对这些分子的影响对于移植结果至关重要.
研究的目的:
- 为了比较不同免疫抑制诱导疗法的对移植患者Perforin和Granzyme B转录的影响.
- 为了研究临床参数与这些移植后的转录水平的关联.
主要方法:
- 量化实时PCR用于测量408名脏移植接受者的Perforin和Granzyme B转录.
- 不同的捐赠者类型和诱导疗法之间的转录水平的比较.
- 进行了接收机操作员特征和回归分析.
主要成果:
- 与健康对照人群相比,移植患者的珀福林转录率较低.
- 与其他疗法相比,胸球蛋白诱导疗法显著降低了Perforin和Granzyme B的转录.
- 珀福林和Granzyme B水平表明含有胆红蛋白的诱导疗法.
- 降低的血肌和HLA不匹配与高的Perforin/Granzyme B转录比率相关.
结论:
- 临床参数和特定的免疫抑制疗法,如胸球蛋白,显著影响移植后的Perforin和Granzyme B转录水平.
- 这些发现强调了诱导疗法对关键免疫标记物的影响,并表明了对移植受体免疫监测的潜在影响.
相关概念视频
01:28Kidney Transplant I: Introduction
827
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
827
01:26Kidney Transplant II: Surgical Procedure
926
Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living...
926